Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04102579 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
A Phase 3 study of Chorea, Huntington, sponsored by Neurocrine Biosciences.
- Completed
- Registry status
- Phase 3
- Development phase
- 128
- Enrollment target
- 20
- Study locations
NCT04102579: Completed Phase 3 study of Chorea, Huntington, sponsored by Neurocrine Biosciences.
NCT04102579 is a Phase 3 study of Chorea, Huntington that has completed, run by Neurocrine Biosciences. The registered enrollment target is 128 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower). The trial reports 20 study locations across 14 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04102579, a Phase 3 study of Chorea, Huntington, has completed, sponsored by Neurocrine Biosciences.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 128 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.
Primary Outcome
The TMC is part of the motor assessment of the UHDRS and measures chorea in 7 different body parts including the face, oral-buccal-lingual region, trunk and each limb independently. The TMC score is the sum of the individual scores and ranges from 0 to 28. A decrease in TMC scores indicates improvement in chorea symptoms.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Valbenazine
Study Locations (20)
California
- Neurocrine Clinical Site - La Jolla
- Neurocrine Clinical Site - Sacramento
Colorado
- Neurocrine Clinical Site - Aurora
- Neurocrine Clinical Site - Englewood
Florida
- Neurocrine Clinical Site - Gainesville
- Neurocrine Clinical Site - Miami
Illinois
- Neurocrine Clinical Site - Chicago
- Neurocrine Clinical Site - Chicago
Kansas
- Neurocrine Clinical Site - Kansas City
- Neurocrine Clinical Site - Wichita
Massachusetts
- Neurocrine Clinical Site - Boston
- Neurocrine Clinical Site - Boston
Alabama
- Neurocrine Clinical Site - Birmingham
Arkansas
- Neurocrine Clinical Site - Little Rock
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 128 participants |
| Start Date | 2019-11-13 |
| Est. Completion | 2021-10-26 |
| Phase | Phase 3 |
What the finished NCT04102579 record still lists
NCT04102579 is an interventional study that assigns participants to a tested intervention. The registered 128 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (83% lower).
The record links to 1 condition, with Chorea, Huntington appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT04102579 names 20 study sites across 14 states, led by California, Colorado, Florida.
Frequently Asked Questions
What is clinical trial NCT04102579 about?
NCT04102579 is a clinical study titled "Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease". This is a Phase 3, randomized, double-blind, placebo-controlled study to evaluate the efficacy, safety, and tolerability of valbenazine to treat chorea in participants with Huntington disease.
What is the current status of trial NCT04102579?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 128 participants. The study started on 2019-11-13. Estimated completion is 2021-10-26.
What conditions does trial NCT04102579 study?
This clinical trial studies the following conditions: Chorea, Huntington.
What interventions are being tested in trial NCT04102579?
The interventions under investigation include: Placebo (DRUG), Valbenazine (DRUG).
Who is sponsoring clinical trial NCT04102579?
This trial is sponsored by Neurocrine Biosciences, which has 65 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04102579 being conducted?
This trial has 20 study locations across Alabama, Arkansas, California, Colorado, District of Columbia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Chorea, Huntington
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04102579's enrollment target sits among peer trials
128 1601st of 2000 higher than 399 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02870738 · 128 participants · Phase 2
Bladder Directed vs. Pelvic Floor Therapy in IC/BPS
- NCT03294460 · 128 participants · Phase 1
Nicotinic Receptor Genetic Variation and Alcohol Reward
- NCT04149977 · 128 participants · NA
Blood Flow Restriction Therapy in Lower Limb Extensor Injuries
- NCT04373057 · 128 participants · Phase 1
Prebiotic Galacto-oligosaccharide and Acute GVHD
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI